Metastatic Prostate Cancer
Penn researchers receive grant to develop CAR-T for advanced prostate cancer
FDA grants priority review to Rubraca for advanced prostate cancer
Cabazitaxel improves outcomes among certain men with metastatic prostate cancer

BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with previously treated metastatic castration-resistant prostate cancer, according to results of the randomized CARD study presented at European Society for Medical Oncology Congress.
Addition of docetaxel to androgren deprivation confers durable OS benefit for metastatic prostate cancer

BARCELONA, Spain — The addition of upfront docetaxel chemotherapy to androgen deprivation therapy conferred durable, clinically significant benefit for men with low- and high-burden metastatic prostate cancer, according to results of the randomized phase 3 STAMPEDE trial presented at European Society for Medical Oncology Congress.